T-cell receptor retrogenic mice: A rapid, flexible alternative to T-cell receptor transgenic mice

Immunology

Volumn 136, Issue 3, 2012, Pages 265-272

  Bettini, Matthew L ^a   Bettini, Maria ^a   Vignali, Dario A A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

2A peptide; Autoimmunity; CD3; Retrogenic; T cell receptor; Transgenic

Indexed keywords

RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR;

ARTICLE; AUTOIMMUNITY; CELL COUNT; CISTRON; COST; EXPERIMENTAL MOUSE; FOUNDER EFFECT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; RECEPTOR INTRINSIC ACTIVITY; RETROGENIC MOUSE; T LYMPHOCYTE; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; GENES; GENETIC TECHNIQUES; GENETIC VECTORS; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; RECEPTORS, ANTIGEN, T-CELL; RETROVIRIDAE; T-LYMPHOCYTES;

EID: 84861733007     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2012.03574.x     Document Type: Article

References (66)

1. Palmer E. Negative selection - clearing out the bad apples from the T-cell repertoire. Nat Rev Immunol 2003; 3:383-91.
2. Hogquist KA. Signal strength in thymic selection and lineage commitment. Curr Opin Immunol 2001; 13:225-31.
3. Allen PM. Peptides in positive and negative selection: a delicate balance. Cell 1994; 76:593-6.
4. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008; 8:523-32.
5. Stockinger B. T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms. Adv Immunol 1999; 71:229-65.
6. Zehn D, Lee SY, Bevan MJ. Complete but curtailed T-cell response to very low-affinity antigen. Nature 2009; 458:211-4.
7. Savage PA, Boniface JJ, Davis MM. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity 1999; 10:485-92.
8. Kim C, Williams MA. Nature and nurture: T-cell receptor-dependent and T-cell receptor-independent differentiation cues in the selection of the memory T-cell pool. Immunology 2010; 131:310-7.
9. Lanzavecchia A, Sallusto F. Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol 2002; 2:982-7.
10. Malherbe L, Hausl C, Teyton L, McHeyzer-Williams MG. Clonal selection of helper T cells is determined by an affinity threshold with no further skewing of TCR binding properties. Immunity 2004; 21:669-79.
11. + T cell responses in vivo and in vitro. Proc Natl Acad Sci U S A 1999; 96:9781-6.
12. + regulatory T cells induced by an agonist self-peptide. Nat Immunol 2001; 2:301-6.
13. + regulatory T-cell selection. Immunol Rev 2006; 212:74-85.
14. Janeway CA Jr. The T cell receptor as a multicomponent signalling machine: CD4/CD8 coreceptors and CD45 in T cell activation. Annu Rev Immunol 1992; 10:645-74.
15. Nikolich-Zugich J, Slifka MK, Messaoudi I. The many important facets of T-cell repertoire diversity. Nat Rev Immunol 2004; 4:123-32.
16. + thymocytes. Nature 1988; 333:742-6.
17. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76:17-27.
18. Williams CB, Engle DL, Kersh GJ, White JM, Allen PM. A kinetic threshold between negative and positive selection based on the longevity of the T cell receptor-ligand complex. J Exp Med 1999; 189:1531-44.
19. Holst J, Szymczak-Workman AL, Vignali KM, Burton AR, Workman CJ, Vignali DA. Generation of T-cell receptor retrogenic mice. Nat Protoc 2006; 1:406-17.
20. Holst J, Vignali KM, Burton AR, Vignali DA. Rapid analysis of T-cell selection in vivo using T cell-receptor retrogenic mice. Nat Methods 2006; 3:191-7.
21. Donnelly ML, Luke G, Mehrotra A, Li X, Hughes LE, Gani D, Ryan MD. Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J Gen Virol 2001; 82(Pt 5): 1013-25.
22. Donnelly ML, Hughes LE, Luke G, Mendoza H, ten Dam E, Gani D, Ryan MD. The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. J Gen Virol 2001; 82(Pt 5): 1027-41.
23. de Felipe P. Skipping the co-expression problem: the new 2A "CHYSEL" technology. Genet Vaccines Ther 2004; 2:13.
24. Atkins JF, Wills NM, Loughran G, Wu CY, Parsawar K, Ryan MD, Wang CH, Nelson CC. A case for "StopGo": reprogramming translation to augment codon meaning of GGN by promoting unconventional termination (Stop) after addition of glycine and then allowing continued translation (Go). RNA 2007; 13:803-10.
25. Doronina VA, Wu C, de Felipe P, Sachs MS, Ryan MD, Brown JD. Site-specific release of nascent chains from ribosomes at a sense codon. Mol Cell Biol 2008; 28:4227-39.
26. Szymczak AL, Vignali DA. Development of 2A peptide-based strategies in the design of multicistronic vectors. Expert Opin Biol Ther 2005; 5:627-38.
27. Klump H, Schiedlmeier B, Vogt B, Ryan M, Ostertag W, Baum C. Retroviral vector-mediated expression of HoxB4 in hematopoietic cells using a novel coexpression strategy. Gene Ther 2001; 8:811-7.
28. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF, Vignali DA. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 2004; 22:589-94.
29. Percy N, Barclay WS, Garcia-Sastre A, Palese P. Expression of a foreign protein by influenza A virus. J Virol 1994; 68:4486-92.
30. Chaplin PJ, Camon EB, Villarreal-Ramos B, Flint M, Ryan MD, Collins RA. Production of interleukin-12 as a self-processing 2A polypeptide. J Interferon Cytokine Res 1999; 19:235-41.
31. Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA, Lotze MT. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 1995; 155:1393-403.
32. Tahara H, Zitvogel L, Storkus WJ et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995; 154:6466-74.
33. Lorens JB, Pearsall DM, Swift SE et al. Stable, stoichiometric delivery of diverse protein functions. J Biochem Biophys Methods 2004; 58:101-10.
34. Szymczak AL, Workman CJ, Gil D, Dilioglou S, Vignali KM, Palmer E, Vignali DA. The CD3ε proline-rich sequence, and its interaction with Nck, is not required for T cell development and function. J Immunol 2005; 175:270-5.
35. Szymczak AL, Vignali DA. Plasticity and rigidity in adaptor protein-2-mediated internalization of the TCR:CD3 complex. J Immunol 2005; 174:4153-60.
36. Wang H, Holst J, Woo SR et al. Tonic ubiquitylation controls T-cell receptor: CD3 complex expression during T-cell development. EMBO J 2010; 29:1285-98.
37. Furmanski AL, Ferreira C, Bartok I et al. Public T cell receptor β-chains are not advantaged during positive selection. J Immunol 2008; 180:1029-39.
38. Bartok I, Holland SJ, Kessels HW, Silk JD, Alkhinji M, Dyson J. T cell receptor CDR3 loops influence αβ pairing. Mol Immunol 2010; 8:1613-8.
39. Holst J, Wang H, Eder KD et al. Scalable signaling mediated by T cell antigen receptor-CD3 ITAMs ensures effective negative selection and prevents autoimmunity. Nat Immunol 2008; 9:658-66.
40. Arnold PY, Burton AR, Vignali DA. Diabetes incidence is unaltered in glutamate decarboxylase 65-specific TCR retrogenic nonobese diabetic mice: generation by retroviral-mediated stem cell gene transfer. J Immunol 2004; 173:3103-11.
41. Burton AR, Vincent E, Arnold PY et al. On the pathogenicity of autoantigen-specific T-cell receptors. Diabetes 2008; 57:1321-30.
42. + T cells. J Immunol 2010; 184:4863-70.
43. Lennon GP, Bettini M, Burton AR, Vincent E, Arnold PY, Santamaria P, Vignali DA. T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. Immunity 2009; 31:643-53.
44. Yang L, Qin XF, Baltimore D, Van Parijs L. Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells. Proc Natl Acad Sci U S A 2002; 99:6204-9.
45. Yang L, Baltimore D. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proc Natl Acad Sci U S A 2005; 102:4518-23.
46. Alli R, Nguyen P, Geiger TL. Retrogenic modeling of experimental allergic encephalomyelitis associates T cell frequency but not TCR functional affinity with pathogenicity. J Immunol 2008; 181:136-45.
47. Chaparro RJ, Burton AR, Serreze DV, Vignali DA, DiLorenzo TP. Rapid identification of MHC class I-restricted antigens relevant to autoimmune diabetes using retrogenic T cells. J Immunol Methods 2008; 2:106-15.
48. Kobayashi M, Jasinski J, Liu E et al. Conserved T cell receptor α-chain induces insulin autoantibodies. Proc Natl Acad Sci U S A 2008; 105:10090-4.
49. Viret C, Leung-Theung-Long S, Serre L, Lamare C, Vignali DA, Malissen B, Carrier A, Guerder S. Thymus-specific serine protease controls autoreactive CD4 T cell development and autoimmune diabetes in mice. J Clin Invest 2011; 121:1810-21.
50. + T cells respond to Chlamydia trachomatis in the genital mucosa. J Immunol 2006; 177:7974-9.
51. Mallevaey T, Scott-Browne JP, Matsuda JL et al. T cell receptor CDR2 β and CDR3 β loops collaborate functionally to shape the iNKT cell repertoire. Immunity 2009; 31:60-71.
52. Furmanski AL, Bartok I, Chai JG et al. Peptide-specific, TCR-α-driven, coreceptor-independent negative selection in TCR-α-chain transgenic mice. J Immunol 2010; 184:650-7.
53. Zhang L, Jasinski JM, Kobayashi M et al. Analysis of T cell receptor β chains that combine with dominant conserved TRAV5D-4*04 anti-insulin B:9-23 α chains. J Autoimmun 2009; 33:42-9.
54. Zhang L, Jin N, Nakayama M, O'Brien RL, Eisenbarth GS, Born WK. γδ T cell receptors confer autonomous responsiveness to the insulin-peptide B:9-23. J Autoimmun 2010; 34:478-84.
55. Verdaguer J, Schmidt D, Amrani A, Anderson B, Averill N, Santamaria P. Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice. J Exp Med 1997; 186:1663-76.
56. Katz JD, Wang B, Haskins K, Benoist C, Mathis D. Following a diabetogenic T cell from genesis through pathogenesis. Cell 1993; 74:1089-100.
57. Jasinski JM, Yu L, Nakayama M, Li MM, Lipes MA, Eisenbarth GS, Liu E. Transgenic insulin (B:9-23) T-cell receptor mice develop autoimmune diabetes dependent upon RAG genotype, H-2g7 homozygosity, and insulin 2 gene knockout. Diabetes 2006; 55:1978-84.
58. Dash P, McClaren JL, Oguin TH 3rd et al. Paired analysis of TCRα and TCRβ chains at the single-cell level in mice. J Clin Invest 2011; 121:288-95.
59. Csikos T, Reijmers RM, Uren AG, Spaargaren M, Pals ST. Instant conditional transgenesis in the mouse hematopoietic compartment. J Immunol Methods 2008; 339:259-63.
60. Lieu ZZ, Lock JG, Hammond LA, La Gruta NL, Stow JL, Gleeson PA. A trans-Golgi network golgin is required for the regulated secretion of TNF in activated macrophages in vivo. Proc Natl Acad Sci U S A 2008; 105:3351-6.
61. Collison LW, Workman CJ, Kuo TT et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450:566-9.
62. Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010; 116:1035-44.
63. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73.
64. Vatakis DN, Koya RC, Nixon CC et al. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci U S A 2011; 108:E1408-16.
65. Ha SP, Klemen ND, Kinnebrew GH et al. Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity. J Clin Invest 2010; 120:4273-88.
66. Joseph A, Zheng JH, Follenzi A et al. Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity. J Virol 2008; 82:3078-89.